Freedy, A., Wiredja, D., Zhang, J., McMahon, C., Angelos, M., Amaya, M., Gutman, J., Schwartz, M., Pollyea, D., Kent, A. (2025). Patients with AML with an IDH2 R172K mutation have improved overall survival with venetoclax + azacitidine as compared to those with IDH2 R140Q mutations. Blood. https://doi.org/10.1182/blood-2025-7018